FDA Brief

Warning letters Drugs

FDA warning letter to

Maximus Health, Inc. dba Maximus

LowIssued Jun 8Posted Jun 16Center for Drug Evaluation and Research (CDER)

FDA warned Maximus Health that its website makes false or misleading claims about compounded semaglutide and tirzepatide.

What happened

During a May 2026 review of Maximus’s website, FDA found that the site offered compounded semaglutide and tirzepatide products and made claims such as “Clinically studied ingredients” and “Proven to lose weight effectively.” FDA also said the site described the products’ sources as “FDA approved pharmacies.” FDA cited these statements as false or misleading because compounded drug products and compounding pharmacies or outsourcing facilities are not FDA-approved.

What FDA found

  1. The website’s claims that the compounded semaglutide and tirzepatide products have “clinically studied ingredients” and are “proven to lose weight effectively” falsely suggest FDA approval or evaluation.

    FD&C Act §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]
  2. The website says the products are sourced from “FDA approved pharmacies,” which falsely implies compounding pharmacies or outsourcing facilities are FDA-approved or licensed.

    FD&C Act §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]
  3. FDA said these misbranded products were introduced or delivered for introduction into interstate commerce.

    FD&C Act § 301(a) [21 U.S.C. § 331(a)]

What FDA wants

FDA asks Maximus to investigate root causes and take corrective and preventive actions, and to send a written response to FDA’s Office of Compounding Quality and Compliance within 15 business days. The response should identify the entities that produce the compounded products, include a sample of labeling, and address the false or misleading website claims.

Who should pay attention

  • telehealth companies selling compounded semaglutide or tirzepatide
  • compounding pharmacies and outsourcing facilities named in marketing
  • marketing and compliance teams for online pharmacy websites

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low